Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 9
Submit an article Journal homepage
192
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Estimating the impact of early bendamustine failure on feasibility of subsequent CAR-T cell therapy in mantle cell lymphoma

Robert Puckrina Tom Baker Cancer Centre, and University of Calgary, Calgary, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8918-6598View further author information
ORCID Icon,
Carolyn Owena Tom Baker Cancer Centre, and University of Calgary, Calgary, CanadaView further author information
,
Lesley Streeta Tom Baker Cancer Centre, and University of Calgary, Calgary, CanadaView further author information
,
Sarah Perrya Tom Baker Cancer Centre, and University of Calgary, Calgary, CanadaView further author information
,
Anthea Petersb Cross Cancer Institute and University of Alberta, Edmonton, CanadaView further author information
&
Douglas Stewarta Tom Baker Cancer Centre, and University of Calgary, Calgary, CanadaView further author information
Pages 1596-1599 | Received 13 Mar 2023, Accepted 07 Jun 2023, Published online: 20 Jun 2023

References

  • Narkhede M, Goyal G, Shea L, et al. Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv. 2022;6(14):4122–4131. doi: 10.1182/bloodadvances.2022007247.
  • Martin P, Cohen JB, Wang M, et al. Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma: results from large real-world cohorts. J Clin Oncol. 2023;41(3):541.
  • Villa D, Sehn LH, Savage KJ, et al. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma. Blood Adv. 2020;4(15):3486–3494. doi: 10.1182/bloodadvances.2020002068.
  • Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210. doi: 10.1016/S0140-6736(12)61763-2.
  • Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–2952. doi: 10.1182/blood-2013-11-531327.
  • Chen RW, Li H, Bernstein SH, et al. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG study S1106. Br J Haematol. 2017;176(5):759–769. doi: 10.1111/bjh.14480.
  • Flinn IW, van der Jagt R, Kahl B, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-Year Follow-Up study. J Clin Oncol. 2019;37(12):984–991. doi: 10.1200/JCO.18.00605.
  • Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022;386(26):2482–2494. doi: 10.1056/NEJMoa2201817.
  • Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555.
  • Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2023;41(14):2594-606.
  • Iacoboni G, Martin Lopez AN, Jalowiec KA, et al. Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy. Blood. 2022;140(Supplement 1):1592–1594. doi: 10.1182/blood-2022-169783.
  • Jo T, Yoshihara S, Okuyama Y, et al. Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan. Br J Haematol. 2023 Apr 25. [Online ahead of print.]
  • Saito H, Maruyama D, Maeshima AM, et al. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer J. 2015;5(10):e362. doi: 10.1038/bcj.2015.86.
  • Martínez-Calle N, Hartley S, Ahearne M, et al. Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis. Br J Haematol. 2019;184(6):957–968.
  • Duell J, Lukic DS, Karg M, et al. Functionally defective T cells after chemotherapy of B-cell malignancies can be activated by the tetravalent bispecific CD19/CD3 antibody AFM11. J Immunother. 2019;42(5):180–188. doi: 10.1097/CJI.0000000000000267.
  • Merryman RW, Edwin N, Redd R, et al. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020;4(5):858–867. doi: 10.1182/bloodadvances.2019001355.
  • Armand P, Redd R, Bsat J, et al. A phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016;173(1):89–95. doi: 10.1111/bjh.13929.
  • Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma [published correction appears in blood. 2008 jun 15;111(12):5761]. Blood. 2008;111(2):558–565. doi: 10.1182/blood-2007-06-095331.
  • Klapper W, Hoster E, Determann O, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL network. J Hematop. 2009;2(2):103–111. doi: 10.1007/s12308-009-0036-x.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.